ATE106726T1 - Angiogenese hemmendes mittel. - Google Patents
Angiogenese hemmendes mittel.Info
- Publication number
- ATE106726T1 ATE106726T1 AT89116053T AT89116053T ATE106726T1 AT E106726 T1 ATE106726 T1 AT E106726T1 AT 89116053 T AT89116053 T AT 89116053T AT 89116053 T AT89116053 T AT 89116053T AT E106726 T1 ATE106726 T1 AT E106726T1
- Authority
- AT
- Austria
- Prior art keywords
- angiogenesis inhibiting
- inhibiting agent
- angiogenesis
- prophylaxis
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21928788 | 1988-09-01 | ||
| JP5353789 | 1989-03-06 | ||
| US39198089A | 1989-08-10 | 1989-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE106726T1 true ATE106726T1 (de) | 1994-06-15 |
Family
ID=27294982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89116053T ATE106726T1 (de) | 1988-09-01 | 1989-08-31 | Angiogenese hemmendes mittel. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0357061B1 (de) |
| KR (1) | KR0141692B1 (de) |
| AT (1) | ATE106726T1 (de) |
| CA (1) | CA1329771C (de) |
| DE (1) | DE68915900T2 (de) |
| ES (1) | ES2053890T3 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH26256A (en) * | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| DE68927904T2 (de) * | 1988-09-01 | 1997-09-04 | Takeda Chemical Industries Ltd | Fumagillol-Derivate |
| TW282399B (de) * | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
| ATE130517T1 (de) * | 1990-08-08 | 1995-12-15 | Takeda Chemical Industries Ltd | Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff. |
| NZ240214A (en) | 1990-10-16 | 1993-02-25 | Takeda Chemical Industries Ltd | Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs |
| EP0519428B1 (de) * | 1991-06-21 | 2000-09-20 | Takeda Chemical Industries, Ltd. | Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate |
| US6476011B1 (en) | 1991-08-28 | 2002-11-05 | Sterix Limited | Methods for introducing an estrogenic compound |
| US6011024A (en) | 1991-08-28 | 2000-01-04 | Imperial College Of Science Technology & Medicine | Steroid sulphatase inhibitors |
| US6903084B2 (en) | 1991-08-29 | 2005-06-07 | Sterix Limited | Steroid sulphatase inhibitors |
| CA2119233A1 (en) * | 1991-09-18 | 1993-04-01 | Fumio Shimojo | Transocular pharmaceutical preparation |
| JPH06157344A (ja) * | 1992-02-07 | 1994-06-03 | Childrens Medical Center Corp:The | 血管新生阻害のための医薬製剤及び血管新生阻害方法 |
| ATE161716T1 (de) | 1992-08-07 | 1998-01-15 | Takeda Chemical Industries Ltd | Herstellung von mikrokapseln, die wasserlösliche arzneimittel enthalten |
| DE69311278T2 (de) * | 1992-12-16 | 1997-10-30 | Takeda Chemical Industries Ltd | Stabile pharmazeutische Zubereitung mit Fumagillolderivaten |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US8143283B1 (en) | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
| US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US5290887A (en) * | 1993-04-30 | 1994-03-01 | The Dow Chemical Company | Epoxy resins containing thiadiazole and/or oxadiazole moieties |
| US5387657A (en) * | 1993-09-10 | 1995-02-07 | The Dow Chemical Company | Epoxy resins containing thiadiazole and/or oxadiazole moieties |
| EP0800385B1 (de) * | 1994-09-30 | 2000-12-20 | Takeda Chemical Industries, Ltd. | Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe |
| US6117455A (en) * | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
| US5710148A (en) * | 1995-03-06 | 1998-01-20 | Senju Pharmaceuticals Co., Ltd. | Corneal opacification inhibitory composition |
| US5837281A (en) | 1995-03-17 | 1998-11-17 | Takeda Chemical Industries, Ltd. | Stabilized interface for iontophoresis |
| FR2733499B1 (fr) * | 1995-04-27 | 1997-05-30 | Adir | Nouvelles tetrahydropyrano(3,2-d)oxazolones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2733498B1 (fr) * | 1995-04-27 | 1997-05-30 | Adir | Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP0813887A3 (de) * | 1996-06-20 | 1999-11-03 | Hisamitsu Pharmaceutical Co. Inc. | Iontophoretische Vorrichtung |
| CA2210600A1 (en) * | 1996-07-17 | 1998-01-17 | Takashi Houkan | Inhibitor of tumor metastasis or recurrence |
| AU3968597A (en) * | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
| JP2002513391A (ja) | 1996-11-05 | 2002-05-08 | ザ チルドレンズ メディカル センター コーポレイション | 血管形成の抑制のための方法と組成物 |
| US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
| KR100357541B1 (ko) * | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
| KR100357542B1 (ko) * | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| JP4414517B2 (ja) | 1999-09-01 | 2010-02-10 | 久光製薬株式会社 | イオントフォレーシス用デバイス構造体 |
| US7335650B2 (en) | 2000-01-14 | 2008-02-26 | Sterix Limited | Composition |
| AU3947902A (en) | 2000-11-01 | 2002-06-03 | Praecis Pharm Inc | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US6919307B2 (en) | 2000-11-01 | 2005-07-19 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US7105482B2 (en) | 2000-11-01 | 2006-09-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| DE60130799T2 (de) | 2000-11-30 | 2008-07-17 | Children's Medical Center Corp., Boston | Synthese von 4-aminothalidomid enantiomeren |
| DE60233420D1 (de) * | 2001-09-27 | 2009-10-01 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| KR100455900B1 (ko) * | 2001-09-27 | 2004-11-12 | 주식회사 아이디알 | 새로운 푸마질롤 유도체 및 그의 제조방법 |
| FR2832149B1 (fr) * | 2001-11-09 | 2006-01-06 | Galderma Res & Dev | Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique |
| US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| EP3697442A4 (de) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | Kombinationstherapien zur behandlung von krebs |
| CA3076859A1 (en) | 2017-10-06 | 2019-04-11 | Tesaro, Inc. | Combination therapies and uses thereof |
| WO2019118612A1 (en) * | 2017-12-12 | 2019-06-20 | Zafgen, Inc. | Targeting compounds |
| WO2023156996A1 (en) * | 2022-02-16 | 2023-08-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Metap2 inhibitors and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2806454B2 (ja) * | 1988-01-19 | 1998-09-30 | 武田薬品工業株式会社 | 脈管形成阻止剤 |
-
1989
- 1989-08-31 ES ES89116053T patent/ES2053890T3/es not_active Expired - Lifetime
- 1989-08-31 AT AT89116053T patent/ATE106726T1/de not_active IP Right Cessation
- 1989-08-31 KR KR1019890012555A patent/KR0141692B1/ko not_active IP Right Cessation
- 1989-08-31 EP EP89116053A patent/EP0357061B1/de not_active Expired - Lifetime
- 1989-08-31 DE DE68915900T patent/DE68915900T2/de not_active Expired - Lifetime
- 1989-08-31 CA CA000610069A patent/CA1329771C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0357061A1 (de) | 1990-03-07 |
| CA1329771C (en) | 1994-05-24 |
| ES2053890T3 (es) | 1994-08-01 |
| DE68915900D1 (de) | 1994-07-14 |
| EP0357061B1 (de) | 1994-06-08 |
| DE68915900T2 (de) | 1994-11-24 |
| KR0141692B1 (ko) | 1998-06-01 |
| KR900004333A (ko) | 1990-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE106726T1 (de) | Angiogenese hemmendes mittel. | |
| NO942641L (no) | Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav | |
| ATE69376T1 (de) | Haarwuchsmittel. | |
| NO912758D0 (no) | Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger. | |
| DE69214397D1 (de) | 2-Substituierte Indane-2-Carboxyalkyl-Verbindungen mit Enkephalinase und ACE-Hemmwirkung | |
| DE69220744D1 (de) | 2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung | |
| DE68907423D1 (de) | Behandlung der akne. | |
| DK130387D0 (da) | Transglutaminase inhibitorer | |
| NO172389C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazoler | |
| DK599789D0 (da) | 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler | |
| NO160369C (no) | Analogifremgangsmaate for fremstilling av nye, terapeutiskaktive 1,3-dihydro-6-(1-hydroksy-2-dimetylaminometyl-allyl)-7-hydroksy-furo(3,4-c)-pyridinderivater. | |
| DE69010162D1 (de) | Zusammensetzung zur Behandlung von Entzündung. | |
| NO170886C (no) | Analogifremgangsmaate for fremstilling av nye terapeutisk aktive benzotiofener | |
| DK23289D0 (da) | Disubstituerede pyridinderivater, fremgangsmaade og mellemprodukter til deres fremstilling samt deres anvendelse | |
| NO165545C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive nye oksadiazolimidazo-benzodiazepinderivater. | |
| ATE87204T1 (de) | Anti-retrovirales arzneimittel. | |
| DE3582935D1 (de) | Mittel zur behandlung von erkrankungen der venen und des analbereichs. | |
| DE69115745D1 (de) | Verwendung von Steroidderivaten zur Behandlung der Endometriose | |
| DE69024060D1 (de) | Osteogenesis-stimulierende mittel. | |
| ATE75399T1 (de) | Therapeutikum zur behandlung von magengeschwueren. | |
| DE3674321D1 (de) | Behandlung geschmeidiger gewebe. | |
| ES2160102T3 (es) | Tratamiento del eritema provocado por uv. | |
| NO890245D0 (no) | Isoxazoler med nootrop aktivitet. | |
| ATE54413T1 (de) | In der dermatologie anwendbare und imidazolidinylurea als aktiven grundbestandteil enthaltende therapeutische zusammensetzung. | |
| ATE91231T1 (de) | Behandlung der akne. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EEFA | Change of the company name | ||
| EELA | Cancelled due to lapse of time |